Total Payments
$4,661
2024 Payments
$712.48
Companies
32
Transactions
277
Medicare Patients
3,574
Medicare Billing
$455,771
Payment Breakdown by Category
Food & Beverage$4,496 (96.5%)
Education$165.45 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,496 | 270 | 96.5% |
| Education | $165.45 | 7 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $830.27 | 55 | $0 (2024) |
| GlaxoSmithKline, LLC. | $668.37 | 48 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $629.75 | 34 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $372.28 | 26 | $0 (2021) |
| Grifols USA, LLC | $345.99 | 19 | $0 (2024) |
| Mylan Specialty L.P. | $255.15 | 11 | $0 (2024) |
| Insmed, Inc. | $227.78 | 11 | $0 (2023) |
| Genentech USA, Inc. | $196.42 | 14 | $0 (2019) |
| GENZYME CORPORATION | $145.89 | 6 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $143.75 | 9 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $712.48 | 30 | AstraZeneca Pharmaceuticals LP ($150.68) |
| 2023 | $258.13 | 14 | GlaxoSmithKline, LLC. ($65.84) |
| 2022 | $331.86 | 20 | GlaxoSmithKline, LLC. ($124.23) |
| 2021 | $612.04 | 34 | Boehringer Ingelheim Pharmaceuticals, Inc. ($97.30) |
| 2020 | $567.31 | 29 | Insmed, Inc. ($122.33) |
| 2019 | $853.69 | 57 | Boehringer Ingelheim Pharmaceuticals, Inc. ($176.03) |
| 2018 | $638.16 | 42 | Boehringer Ingelheim Pharmaceuticals, Inc. ($135.97) |
| 2017 | $687.32 | 51 | Boehringer Ingelheim Pharmaceuticals, Inc. ($148.15) |
All Payment Transactions
277 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Pulmonology | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: VACCINE | ||||||
| 10/03/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $36.15 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Respiratory | ||||||
| 09/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/24/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Pulmonology | ||||||
| 09/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Respiratory | ||||||
| 09/03/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: RESPIRATORY | ||||||
| 08/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: RESPIRATORY | ||||||
| 07/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.83 | General |
| Category: Immunology | ||||||
| 07/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: RESPIRATORY | ||||||
| 07/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/16/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $33.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $11.71 | General |
| Category: RESPIRATORY | ||||||
| 05/28/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/22/2024 | Baxter Healthcare | Hillrom - Monarch Airway Clearance System (Device) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Airway Clearance Device | ||||||
| 05/16/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Inflammation | ||||||
| 05/07/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: IMMUNOLOGY | ||||||
| 03/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: RESPIRATORY | ||||||
| 03/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: RESPIRATORY | ||||||
| 03/15/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: IMMUNOLOGY | ||||||
| 02/29/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Infections and Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 669 | 942 | $285,813 | $80,842 |
| 2022 | 13 | 750 | 1,091 | $340,666 | $91,863 |
| 2021 | 16 | 1,085 | 1,621 | $521,807 | $143,731 |
| 2020 | 18 | 1,070 | 1,543 | $433,388 | $139,335 |
Total Patients
3,574
Total Services
5,197
Medicare Billing
$455,771
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 96 | 190 | $122,550 | $29,965 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 121 | 187 | $52,921 | $16,742 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 150 | $37,200 | $12,850 | 34.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 142 | $29,962 | $8,377 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $9,963 | $3,400 | 34.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 25 | $11,700 | $3,183 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 50 | $8,500 | $3,075 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 14 | $4,578 | $1,740 | 38.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 11 | $1,496 | $414.15 | 27.7% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 43 | 44 | $2,200 | $388.08 | 17.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 50 | 51 | $3,009 | $379.72 | 12.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 50 | 51 | $1,734 | $327.49 | 18.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 109 | 172 | $110,940 | $28,129 | 25.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 196 | 356 | $100,748 | $27,333 | 27.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 116 | $28,768 | $10,762 | 37.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 115 | 189 | $39,879 | $10,064 | 25.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 55 | 55 | $25,740 | $8,307 | 32.3% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 19 | 27 | $7,695 | $2,240 | 29.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $5,535 | $1,862 | 33.6% |
| 31645 | Aspiration of initial secretion of lung airway using an endoscope | Facility | 2022 | 11 | 11 | $11,141 | $1,173 | 10.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 25 | 26 | $4,420 | $1,083 | 24.5% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 36 | 37 | $1,850 | $326.92 | 17.7% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 38 | 39 | $1,326 | $255.25 | 19.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 29 | 32 | $1,888 | $232.92 | 12.3% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 16 | 16 | $736.00 | $95.10 | 12.9% |
About Dr. David Ryon, MD
Dr. David Ryon, MD is a Pulmonary Disease healthcare provider based in Evansville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740230267.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ryon, MD has received a total of $4,661 in payments from pharmaceutical and medical device companies, with $712.48 received in 2024. These payments were reported across 277 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($4,496).
As a Medicare-enrolled provider, Ryon has provided services to 3,574 Medicare beneficiaries, totaling 5,197 services with total Medicare billing of $455,771. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Internal Medicine
- Location Evansville, IN
- Active Since 05/12/2006
- Last Updated 03/08/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1740230267
Products in Payments
- OFEV (Drug) $432.39
- TRELEGY ELLIPTA (Drug) $378.42
- DUPIXENT (Biological) $272.41
- Arikayce (Drug) $227.78
- Prolastin-C Liquid (Biological) $213.01
- SYMBICORT (Drug) $199.23
- STIOLTO RESPIMAT (Drug) $178.73
- FASENRA (Biological) $168.90
- FASENRA (Drug) $166.27
- STIOLTO (Drug) $158.42
- Yupelri (Drug) $154.33
- LONHALA MAGNAIR (Drug) $153.48
- Prolastin-C (Biological) $132.98
- Esbriet (Biological) $125.58
- NUCALA (Biological) $106.37
- BREO (Drug) $104.64
- YUPELRI (Drug) $100.82
- BROVANA (Drug) $84.41
- Xolair (Biological) $70.84
- BREZTRI (Drug) $69.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Evansville
Dr. Victor Chavez, Md, MD
Pulmonary Disease — Payments: $54,982
Pulmonary Disease $54,982
Raghav Gupta, M.d, M.D
Pulmonary Disease — Payments: $10,683
Pulmonary Disease $10,683
Ahmed Jawad, Md, MD
Pulmonary Disease — Payments: $6,207
Pulmonary Disease $6,207
Dr. Matthew Tucker, D.o, D.O
Pulmonary Disease — Payments: $5,846
Pulmonary Disease $5,846
David Harris, M.d, M.D
Pulmonary Disease — Payments: $4,871
Pulmonary Disease $4,871
Khawaja Zaki, M.d, M.D
Pulmonary Disease — Payments: $4,461
Pulmonary Disease $4,461